Vivek Subbiah, MD, MD Anderson Cancer Center

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.

Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.

Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.

Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

Expert panelists weigh in on emerging data from recent presentations on small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.

Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.

Key opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.

Lung cancer expert Anne Chiang, MD, PhD, considers the recent withdrawal of FDA-accelerated approval for nivolumab and pembrolizumab for patients with relapsed extensive-stage small cell lung cancer.

Vivek Subbiah, MD, reviews the safety and efficacy of treatment with lurbinectedin in patients who have platinum-sensitive relapsed small cell lung cancer.

Panelists reflect on treatment considerations for asymptomatic brain metastases, progress in biomarker research, and frequency of administering checkpoint inhibitors.

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy findings of BLU-667 in RET-altered solid tumors in an interview during the 2018 AACR Annual Meeting.